Institute of Traditional Chinese Veterinary Medicine, College of Veterinary Medicine, Nanjing Agricultural University, Nanjing 210095, PR China; MOE Joint International Research Laboratory of Animal Health and Food Safety, College of Veterinary Medicine, Nanjing Agricultural University, Nanjing 210095, PR China.
Institute of Traditional Chinese Veterinary Medicine, College of Veterinary Medicine, Nanjing Agricultural University, Nanjing 210095, PR China; MOE Joint International Research Laboratory of Animal Health and Food Safety, College of Veterinary Medicine, Nanjing Agricultural University, Nanjing 210095, PR China.
Biomater Adv. 2022 Aug;139:213002. doi: 10.1016/j.bioadv.2022.213002. Epub 2022 Jul 5.
In many clinical studies, prebiotics have been used as adjuvant therapy for inflammatory bowel disease (IBD). Phellinus igniarius polysaccharide (PIP) possesses great anti-inflammatory and prebiotic activities. Herein, we developed an orally deliverable PIP-loaded chitosan-modified PLGA nanomedicine (CS-PIPP) to investigate its anti-inflammatory effect in vitro and in vivo. Dextran sodium sulfate (DSS)-induced colitis model was established to evaluate the preventive effect of CS-PIPP on IBD. This study characterized that CS-PIPP had a size of 288.7 ± 5.49 nm, positive zeta potential, and showed good stability over four weeks. The in-vitro study suggested that CS-PIPP had enhanced phagocytosis by macrophages, which could further significantly inhibit M1-like macrophages phenotype and regulate lipopolysaccharide (LPS)-induced inflammatory cytokines. The in-vivo study revealed that CS-PIPP prominently prevented intestinal inflammatory damage and protected the integrity of the intestinal barrier. Moreover, CS-PIPP increased the contents of short-chain fatty acids (SCFAs) and positively regulated the gut microbiota. Specifically, CS-PIPP reduced enteropathogenic microorganisms while increasing the beneficial microbiota, including Lactobacillus and Akkermansia, which revealed the potential of CS-PIPP as prebiotics. Generally, CS-PIPP promoted the anti-inflammatory effect of PIP, so it could be regarded as a novel and potent nanoformulation to treat IBD.
在许多临床研究中，益生菌被用作炎症性肠病（IBD）的辅助治疗。云芝多糖（PIP）具有很强的抗炎和益生菌活性。在此，我们开发了一种可口服的壳聚糖修饰的 PLGA 纳米药物（CS-PIPP）来研究其在体内和体外的抗炎作用。我们建立了葡聚糖硫酸钠（DSS）诱导的结肠炎模型来评估 CS-PIPP 对 IBD 的预防作用。本研究表明 CS-PIPP 的粒径为 288.7±5.49nm，具有正的zeta 电位，并且在四周内表现出良好的稳定性。体外研究表明 CS-PIPP 增强了巨噬细胞的吞噬作用，进一步显著抑制 M1 样巨噬细胞表型，并调节脂多糖（LPS）诱导的炎症细胞因子。体内研究表明 CS-PIPP 显著预防了肠道炎症损伤并保护了肠道屏障的完整性。此外，CS-PIPP 增加了短链脂肪酸（SCFAs）的含量，并正向调节肠道微生物群。具体而言，CS-PIPP 减少了肠道致病菌，同时增加了有益菌，包括乳杆菌和阿克曼菌，这表明 CS-PIPP 作为益生菌的潜力。总的来说，CS-PIPP 促进了 PIP 的抗炎作用，因此它可以被视为一种治疗 IBD 的新型有效纳米制剂。
